Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E8.03 EPS (ttm)30.21 Insider Own0.10% Shs Outstand156.90M Perf Week-2.53%
Market Cap37.30B Forward P/E9.53 EPS next Y25.43 Insider Trans-0.97% Shs Float152.92M Perf Month-8.49%
Income5.08B PEG- EPS next Q5.04 Inst Own88.20% Short Float2.48% Perf Quarter-13.09%
Sales14.26B P/S2.61 EPS this Y44.80% Inst Trans-2.69% Short Ratio2.28 Perf Half Y-19.55%
Book/sh68.57 P/B3.54 EPS next Y-24.26% ROA19.60% Target Price290.37 Perf Year-18.91%
Cash/sh23.28 P/C10.42 EPS next 5Y-4.92% ROE42.40% 52W Range223.25 - 374.99 Perf YTD-18.27%
Dividend- P/FCF5.85 EPS past 5Y20.50% ROI30.50% 52W High-35.81% Beta0.54
Dividend %- Quick Ratio1.80 Sales past 5Y8.20% Gross Margin87.60% 52W Low7.81% ATR13.93
Employees7400 Current Ratio2.10 Sales Q/Q-6.20% Oper. Margin46.70% RSI (14)43.48 Volatility2.37% 5.35%
OptionableYes Debt/Eq0.69 EPS Q/Q-46.80% Profit Margin35.60% Rel Volume0.56 Prev Close242.51
ShortableYes LT Debt/Eq0.69 EarningsOct 21 BMO Payout0.00% Avg Volume1.66M Price240.69
Recom2.70 SMA20-5.60% SMA50-10.34% SMA200-16.68% Volume301,367 Change-0.75%
Nov-10-20Upgrade DZ Bank Hold → Buy $265
Nov-09-20Reiterated H.C. Wainwright Buy $318 → $289
Nov-09-20Downgrade Cowen Outperform → Market Perform $215
Nov-09-20Downgrade BofA Securities Neutral → Underperform $240
Nov-09-20Downgrade Atlantic Equities Neutral → Underweight $175
Nov-04-20Upgrade Wells Fargo Equal Weight → Overweight $390
Nov-04-20Upgrade Jefferies Hold → Buy $450
Nov-04-20Upgrade BofA Securities Underperform → Neutral
Oct-28-20Initiated UBS Neutral $268
Jul-27-20Upgrade Morgan Stanley Underweight → Overweight $263 → $357
Jun-22-20Reiterated RBC Capital Mkts Sector Perform $303 → $273
Jun-22-20Downgrade Barclays Overweight → Equal Weight $370 → $280
Jun-09-20Downgrade Bernstein Outperform → Mkt Perform $360 → $297
Apr-23-20Downgrade Raymond James Mkt Perform → Underperform
Apr-23-20Downgrade Citigroup Neutral → Sell $365 → $240
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-25-20 10:01AM  
06:20AM  
Nov-24-20 08:00PM  
07:52PM  
04:10PM  
01:30PM  
12:00PM  
11:00AM  
10:15AM  
09:12AM  
Nov-23-20 10:00PM  
07:47PM  
06:21PM  
04:45PM  
03:55PM  
03:44PM  
12:28PM  
11:00AM  
06:20AM  
Nov-22-20 05:30PM  
11:00AM  
07:05AM  
03:17AM  
Nov-20-20 07:26PM  
06:00PM  
05:50PM  
04:59PM  
03:10PM  
01:30PM  
01:00PM  
09:33AM  
Nov-19-20 07:52PM  
06:19PM  
05:15PM  
04:15PM  
04:05PM  
03:30PM  
01:30PM  
01:03PM  
01:00PM  
11:45AM  
11:00AM  
10:17AM  
06:40AM  
Nov-18-20 09:15PM  
09:00PM  
08:30PM  
08:17PM  
04:25PM  
04:05PM  
03:50PM  
02:00PM  
01:00PM  
10:40AM  
07:00AM  
06:08AM  
Nov-17-20 03:02PM  
02:46PM  
01:25PM  
11:00AM  
Nov-16-20 10:57PM  
03:35PM  
02:50PM  
01:00PM  
07:30AM  
Nov-15-20 07:04AM  
Nov-14-20 03:30PM  
03:00PM  
07:31AM  
Nov-13-20 08:00PM  
05:00PM  
02:45PM  
02:04PM  
12:09PM  
10:50AM  
Nov-12-20 08:00PM  
07:51PM  
11:18AM  
Nov-11-20 09:49PM  
04:55PM  
10:01AM  
07:30AM  
06:09AM  
05:39AM  
Nov-10-20 01:26PM  
Nov-09-20 06:11PM  
04:28PM  
04:13PM  
01:18PM  
12:55PM  
12:00PM  
11:21AM  
10:05AM  
09:52AM  
09:44AM  
09:38AM  
09:37AM  
09:00AM  
08:22AM  
08:06AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sandrock AlfredEVP, Research & DevelopmentNov 04Sale350.001,500525,00013,066Nov 06 09:39 PM
Gregory GingerEVP, Human ResourcesJul 31Option Exercise0.0021204,786Aug 04 04:12 PM
SHERWIN STEPHEN ADirectorMar 11Option Exercise58.4612,278717,77216,517Mar 12 06:56 PM
SHERWIN STEPHEN ADirectorMar 11Sale295.222,434718,57414,353Mar 12 06:56 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.004,847033,775Feb 19 06:20 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 15Option Exercise0.001,213015,019Feb 19 06:17 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.0044102,672Feb 19 06:13 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 15Option Exercise0.001,553037,261Feb 19 06:09 PM
Kramer RobinVP, Chief Accounting OfficerFeb 12Option Exercise0.001320282Feb 14 06:37 PM
Karp DanielEVP, Corporate DevelopmentFeb 12Option Exercise0.0096001,224Feb 14 06:36 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.001,68004,375Feb 14 06:34 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.003,54705,021Feb 14 06:32 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,15402,337Feb 14 06:30 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerFeb 12Option Exercise0.001,91903,732Feb 14 06:27 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.005,967036,389Feb 14 06:25 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0011,994031,483Feb 14 06:19 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.005,216014,509Feb 14 06:16 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,30202,219Jan 06 04:14 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.